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Abstract
Purpose—Several established optical imaging approaches have been applied, usually in
isolation, to preclinical studies; however, truly useful in vivo imaging may require a simultaneous
combination of imaging modalities to examine dynamic characteristics of cells and tissues. We
developed a new multimode optical imaging system designed to be application-versatile, yielding
high sensitivity, and specificity molecular imaging.
Procedures—We integrated several optical imaging technologies, including fluorescence
intensity, spectral, lifetime, intravital confocal, two-photon excitation, and bioluminescence, into a
single system that enables functional multiscale imaging in animal models.
Results—The approach offers a comprehensive imaging platform for kinetic, quantitative, and
environmental analysis of highly relevant information, with micro-to-macroscopic resolution.
© World Molecular Imaging Society, 2011
Correspondence to: Daniel L. Farkas; dlfarkas@gmail.com.
Conflict of Interest. The authors declare they have no conflicts of interest.
NIH Public Access
Author Manuscript
Mol Imaging Biol. Author manuscript; available in PMC 2012 November 02.
Published in final edited form as:
Mol Imaging Biol. 2012 August ; 14(4): 431–442. doi:10.1007/s11307-011-0517-z.
$watermark-text
$watermark-text
$watermark-text
Applied to small animals in vivo, this provides superior monitoring of processes of interest,
represented here by chemo-/nanoconstruct therapy assessment.
Conclusions—This new system is versatile and can be optimized for various applications, of
which cancer detection and targeted treatment are emphasized here.
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Introduction
Small animal imaging has become widely used as a non-invasive research tool since it
allows the detection of primary and metastatic tumors, as well as monitoring effects of
pharmacological interventions. In the past, it was necessary to—inefficiently—sacrifice the
animals in order to detect tumors or monitor drug molecules inside tissues. Moreover, the
excised tissues are not functional, and thus the normal physiology such as blood flow, cell–
cell interactions, and metabolic activity is suspended, altered, or degraded. These limitations
impede continuous/recurrent and accurate monitoring of biochemical, genetic, and
pharmacological processes in vivo and in the same animal. This encouraged the
development of better methods to track disease at the preclinical level, with imaging of
small animals in vivo emerging as an important approach [1, 2].
Several non-invasive technologies such as ultrasound, X-rays and computed tomography,
magnetic resonance imaging, positron emission tomography, single photon emission
computed tomography, and optical imaging are available for small animal imaging. These
were all originally developed for clinical applications and redesigned for small animal
imaging. Ultrasound, computed tomography, and magnetic resonance imaging are capable
of resolving the anatomy and physiology through the energy–tissue interaction. On the other
hand, positron emission tomography and single photon emission computed tomography
require reporter probes/contrast agents in order to monitor metabolism [1, 3]. Various
optical imaging technologies that range from 2D imaging to 3D tomography of internal
organs and tissues have been developed for small animal imaging [4, 5]. These methods
have several advantages compared to the non-optical modalities, by offering simultaneous
monitoring of multiple targets or molecular pathways, and by being less expensive and less
potentially harmful [1–3].
Within optical technologies, fluorescence intensity imaging is a simple method to
continuously track movements and concentrations of labeled molecules in vivo, based on the
spatial distribution of intensity at a single detected wavelength. This approach allows
monitoring the progression of diseases, the effects of drug candidates on the target
pathology, the pharmacokinetic behavior of drugs, and the treatment outcomes. It is based
on the linear dependence of fluorescence intensity on the accumulated concentration of
labeled molecules [2, 3, 6–10]. However, in the presence of confounding signals from
entities such as endogenous fluorophores, it is very difficult to discriminate and quantify the
fluorescence signal from labeled molecules of interest. Thus, for more accurate imaging in
the presence of such “noise,” it is necessary to use more advanced imaging methods [2, 9].
As a more quantitative optical technology, spectral imaging provides a high-resolution
spectral signature at every pixel of an image, allowing one to identify, separate, and remove
the contribution of background in analyzed fluorescence images. The entire process can be
completed in seconds [9, 11, 12]; additional information may be obtained by comparing
spectra acquired at different excitation wavelengths. On the other hand, fluorescence
lifetime imaging (FLIM) is less dependent on the concentration of fluorophores but can be
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highly sensitive to tissue environment such as intra/extracellular pH distribution, blood flow,
tissue oxygenation, and temperature. Unlike intensity or spectral measurements, FLIM can
show the energy transfer rate from the excited state of fluorophores to their surrounding
environment [13–17], and can be used for localizing diseased tissues such as tumors based
on physiology [18, 19].
Two-photon excitation and intravital confocal imaging methods have been widely utilized
for deep tissue exploration, as they can provide highly resolved information in vivo. In
particular, two-photon excited fluorescence imaging has sectioning capability at the deeper
locations than one-photon excited confocal fluorescence imaging, while exhibiting less
overall photobleaching; therefore, scanning two-photon excitation has been widely used as a
non-invasive imaging method in tissue samples and living animals [20–22]. Intravital
confocal imaging also facilitates high-resolution studies of cellular and molecular events in
vivo [23]. In particular, an optical fiber bundle, properly end-scanned, constitutes a high-
resolution endoscope and can be inserted into a small animal, enabling observation of
microanatomy inside a small animal, with cellular resolution. This technology has already
been broadly utilized, for imaging in vivo, e.g., subcutaneous tumors, peripheral nerves, and
angiogenesis [24, 25]. Finally, bioluminescence imaging enables the non-invasive study of
biological processes without excitation light sources in small animals [14], based on some
advantages over fluorescence imaging: (1) background from excitation and/or tissue
autofluorescence is eliminated, and (2) as a consequence, good signal-to-noise allows
detection of light from an enzymatic reaction at few centimeters depth [10, 26].
All of the optical imaging technologies mentioned have their inherent advantages in
providing particular information when used in isolation. Thus, the use of the specific
imaging technologies depends on the information required in pre-clinical studies. Many
studies may benefit from using multiple imaging modes simultaneously since such a
combination can offer complementary and even synergetic information in detecting diseased
tissues or identifying the characteristics of molecules of interest in vivo. However, most
commercial small animal optical imaging systems are single-mode, thus lacking in
versatility. Although these systems perform well in the tasks they have been designed for,
they do not have enhanced capabilities such as the use of multiple laser excitation sources,
or advanced features such as fluorescence lifetime and two-photon excited fluorescence
imaging. These limitations, and the need we see for more flexible, advanced in vivo
imaging, prompted us to develop a new multimode optical imaging system that can
distinguish multiple targets, provide quantification of fluorochrome biodistribution, and
allow simple switching from macro- to microscopic resolution and between multiple
imaging modes: fluorescence intensity, spectral, lifetime, intravital confocal, two-photon
excited fluorescence, and bioluminescence imaging.
In this work, we demonstrate a new multimode optical imaging system that enables
simultaneous use of these powerful multiscale optical imaging technologies for dynamic,
quantitative, and functional monitoring of multiple fluorophores, discrimination between
them, and the acquisition of highly resolved information in vivo. In addition, after
evaluating each imaging mode by using a biological specimen of choice (including ex vivo
and in vivo), we present their focused use in multimode optical imaging for chemotherapy
research: We have chosen two drug molecules of interest, nanoconstructs [27, 28], and the
complex of a breast cancer-targeted cell penetration protein (HerPBK10) and a sulfonated
gallium corrole (S2Ga), which is denoted HerGa [29, 30]. We show here continuous
fluorescence intensity/spectral imaging for dynamic monitoring and clearance examination
of nanoconstructs in vivo, and the feasibility of multimode optical imaging for better
chemotherapy assessment of HerGa.
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Materials and Methods
Multimode Optical Imaging System
A schematic diagram of the instrument we designed and built is shown in Fig. 1a. It consists
of a light-tight enclosure within which various optical imaging modes are implemented as
follows: fluorescence intensity, spectral, lifetime, intravital confocal, scanning/wide-field
two-photon excited fluorescence (WTEF), which has been developed outside but will be
incorporated into the system, and bioluminescence imaging. A wide selection of light
sources is available, including a tunable femtosecond (fs) pulsed laser (MaiTai,
SpectraPhysics) (710–990 nm), a picosecond pulsed laser (Tsunami, SpectraPhysics; 700–
1,080 nm), and continuous wave (CW) lasers [405 and 670 nm solid-state, HeCd (442 nm),
argon–krypton (488, 514, and 647 nm), and HeNe laser (633 nm)]. The light sources are
delivered via free space, or through a fiber-based delivery system allowing flexible delivery
of various lasers’ output inside a light-tight enclosure. The light is deflected/divided by a
50:50 dichroic mirror and delivered onto specimens through diffusers and mirrors. Here,
uniform laser excitation of the specimen is realized by scattering the laser light onto the 90%
+ transmission broadband diffusers (“ThorLabs, 1” round 20° circle tophat diffuser). Light
from the specimen is collected by a telecentric lens (Melles Griot, Invaritar™ 59LGL428
and 59LGG950, NA: 0.24).
The collected light passes through either (1) standard interference filters (Chroma
Technology) installed in a motorized filter wheel, (2) an Acousto-Optical Tunable Filter
(AOTF) (ChromoDynamics), or (3) a FLIM module with a time-gated intensifier (LaVision
PicoStar HR), before arriving onto a cooled charge-coupled device (CCD) camera
(Princeton Instruments, PIXIS 400) located on top of the light-tight imaging chamber. Every
component is modular, and switching between modes is fast (~seconds, if necessary). The
AOTF and FLIM modules can be flexibly exchanged by using a sliding rail. In addition, for
high-resolution endoscopic imaging, an optical device and its probe (Mauna Kea
Technologies) have been incorporated for intravital confocal imaging in the system. For 3D
fluorescence imaging, the telecentric lens and CCD camera can be attached onto the
enclosure’s sidewall. The synchronization between a rotational stage and CCD camera for
image acquisition with different angle views is controlled by a program we developed.
Furthermore, a two-photon imaging module was developed for high-resolution deep tissue
imaging outside the system and can be integrated within it.
The experimental animal (mouse or rat) is placed inside the light-tight enclosure on a
moving stage that has a spatial resolution of 5 μm in the x and y-axes, 100 μm in the z-axis,
and 2.16 arcsec in the rotational axis. The sample stage can move along x-, y-, z-axis, and
rotate clockwise and counterclockwise to vary the field of view and a sample position. The
stages are actuated by a stepper and a servo motor using software we developed (using CVI/
National Instruments). In order to prevent animals from moving during image acquisition, a
gated anesthesia system we developed (capable of stopping breathing for the duration of
image acquisition alone) that uses a mixture of oxygen and isoflurane is attached to the
imaging box.
Imaging Modes
Fluorescence Intensity Imaging Mode—In this mode, a laser source can be selected
by flipping mirrors for the excitation of a variety of fluorophores. Light from the selected
source is delivered onto a specimen through mirrors, filters, and diffusers. Before a
fluorescence image from the specimen is acquired, a background image including a spatial
profile of an excitation light source is recorded for flat-field correction. Then, fluorescence
collected by a telecentric lens is recorded in a high sensitive cooled CCD camera, after being
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selected by an emission filter in a computer-controlled filter wheel. Finally, the fluorescence
image is corrected by the background image in order to reduce the artifacts due to the profile
of an excitation light source. Meanwhile, a photographic-equivalent image is taken with
LED illumination for overlaying the fluorescence image. Fig. 2a shows the schematic of the
fluorescence imaging mode.
Spectral Imaging Mode—In this mode (Fig. 2b), the laser delivery for excitation of
specimen is the same as in fluorescence intensity imaging. In detection, the emitted
fluorescence from a specimen is collected by a telecentric lens and passes through a long-
pass filter, which rejects the excitation light source. Then, the light is delivered onto a high-
sensitivity, low-noise CCD camera cooled to −70°C (Princeton Instruments, PIXIS 400) for
imaging through an imaging AOTF system (ChromoDynamics, Inc.) which can rapidly and
(random-access) sequentially select a narrow bandwidth (1.5–4.0 nm). After the sequential
images within the certain range of wavelength are acquired, the spectral signatures on each
pixel are generated by our custom-developed program [12]. The image is then classified
based on predefined spectral signatures. In addition, spectral unmixing is performed in order
to reject autofluorescence from fluorescence signals of interest using a module we
incorporated into ImageJ [31].
Fluorescence Lifetime Imaging (FLIM) Mode—For FLIM in multi-mode optical
imaging system, we developed a mosaic FLIM system with fs pulsed laser, for a large field
of view (LFOV) described elsewhere. In this method, fs pulsed laser light is tuned to
400~480 nm, a repetition rate of 80 MHz, generated by the second harmonic of fs tunable
pulsed laser with 800~960 nm in Barium–Borate (BBO) crystal, and used for the excitation
of molecules inside a specimen. An ultra-fast time-gated camera (LaVision, PicoStar HR)
was utilized for FLIM. Fig. 2c shows the schematic of the mosaic FLIM setup. The fs pulsed
laser is delivered through a small opening in a light-tight enclosure; then, the light passes
through two mirrors and a diffuser in order to excite a specimen. The beam size of the light
is controlled by distance between a specimen and the diffuser that induces a 20° divergence
of light. The fluorescence from a specimen is collected by the telecentric lens. The
fluorescence light passes through a selected emission filter, and then is delivered onto the
CCD connected with time-gated intensifier (TGI), synchronized with the pulsed light via a
delay unit that connects with the external trigger. The scanning for LFOV is performed
sequentially after each image acquisition by x–y translation via the motorized stage under
the control of the program that we developed using National Instrument CVI. It can control
scanning width, height, and step size. Also, the program can be connected with a Joystick
program that allows control of the motorized stages and scanning features at different
locations through TCP/IP connection [9].
Intravital Confocal Imaging Mode—Intravital confocal imaging enables in vivo
endoscopic imaging with high resolution, using the proven CellVizio instrument from
Mauna Kea Technologies, used here (Fig. 2d) as a new mode added to our system. In this
mode, we constructed and used a holder for positioning a fiber bundle probe in order to
reduce the artifacts due to operators’ hand movements. The fiber bundle probe is directly
connected with a confocal scanner including a scanning unit, an excitation laser source, an
emission filter, and a detection module (an avalanche photodiode).
Multiphoton (Scanning/WTEF) Imaging Mode—The scanning/WTEF imaging mode
has been developed in order to examine details at deeper locations in multimode optical
imaging in vivo; we first built this capability outside our black box system. For wide-field
non-linear excitation, a polarized fs pulsed laser with 780~990 nm, 50–300 mW average
power, and 80 MHz repetition rate was utilized. The fs pulsed laser beam passes through a
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Faraday rotator, several mirrors, and galvo mirrors. Then, it is focused on the back focal
plane of an objective (Nikon 40×, 1.3 NA, oil, Nikon 40×, 0.75 NA, air, or Nikon 60×, 0.75
NA) through a doublet lens (L1; Melles Griot, FL200) in order to obtain a quasi-parallel
beam which makes a larger spot size at the sample. The fluorescence from a specimen is
collected by the same objective, and then passes through short/band-pass filters and a tube
lens (L2) before being recorded on a cooled CCD. In addition, in order to compensate a non-
uniform excitation generated by the Gaussian profile of the beam, flat-field correction of a
WTEF image was performed by a normalized and inverted Gaussian mask [32]. The
Gaussian mask has been constructed through the convolution of the original image with a
Gaussian function (radius, over 40) at a focal plane using ImageJ. The corrected image, R, is
obtained by the entry-by-entry product of the original image O and the Gaussian mask M
(R=O×M). Moreover, for two-photon excited fluorescence imaging of in vitro specimens, a
scanning unit is incorporated into the system. In the scanning two-photon imaging mode, the
CCD is replaced with a photomultiplier tube (PMT; Hamamatsu, H6780-20), and the
doublet lens (L1) is removed from an optical beam path. Here, galvo mirrors and PMT
output signals are synchronized by the program we developed. Fig. 2e shows the
experimental setup.
Bioluminescence Imaging Mode—A bioluminescence imaging mode was developed in
order to detect ATP and enzymatic activity in engineered nude mice. The experimental setup
is shown in Fig. 2f. A photographic image of the mouse was also recorded, using two light-
emitting diodes. Bioluminescence was collected by a telecentric lens (Melles-Griot,
Invaritar™) and imaged onto a cooled CCD (Princeton Instruments, PIXIS 400). The
bioluminescence image was thresholded and overlapped with the photographic image.
Sample Preparations
Four nude mice and one rat were prepared for the evaluation of each imaging mode. Three
of the mice (provided by the labs of Drs. Lali K. Medina-Kauwe and Julia Ljubimova) bore
bilateral flank tumor xenografts, one mouse has implanted brain tumors, and one is an
engineered mutant mouse. Also, a rat was prepared for intravital confocal imaging. Before
intravital confocal imaging of rat spine is performed, the rat was euthanized, and then the
spine of the rat was exposed. For evaluation of fluorescence intensity imaging, 100 μl of
nanoconstruct solution at a concentration of 2.5 mg/kg was prepared for the tail vein
injection. On the other hand, 10 μM fluorescein solution was diluted by phosphate buffered
saline solution (pH 7.4) for spectral and FLIM. For evaluation of bioluminescence imaging,
we prepared a stock solution of a luciferin enzyme substrate (Xenogen) at 15 mg/ml in
Dulbecco’s phosphate-buffered saline solution, and then injected 100 μl of luciferin into an
abdominal cavity of the engineered mouse. For WTEF imaging, a 16-μm cryostat section of
mouse intestine (specifically, the filamentous actin prevalent in the brush border) stained
with Alexafluor 568 phalloidin (FluoCells slide #4 (F-24631), Invitrogen) was prepared.
Finally, an extracted mouse liver was stained nonspecifically with 500 μM fluorescein
solution for evaluation of scanning two-photon excited fluorescence imaging mode.
In nanoconstruct experiments, epidermal growth factor receptor (EGFR)-positive MDA-MB
468 human breast tumor was implanted into the right posterior mid-dorsum of nude mice
[Tac: Cr:(MCr)-Foxnnu]. After anesthetizing the mouse using the gated anesthesia machine
we built, the 100 μl of nanoconstruct solution was intravenously injected via the tail vein at
a concentration of 2.5 mg/kg [27, 28].
Mice with implanted MDA-MB-435 human breast tumor with over 30mm2 were prepared
for assessment of HerGa in chemotherapy. 46 nmol of HerGa was injected (IV) into the tail
of one mouse for imaging tumor regions using FLIM. In addition, specific organs and
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tumors were extracted from the same mouse at 4 days after intravenous injection of HerGa,
and the organs and tumors were washed with PBS in order to examine the drug
accumulation. In addition, after injection of HerGa into two tumor and non-tumor regions,
we euthanized the mouse as provided by our IACUC protocol. Multimodal imaging of the
mouse was performed to test HerGa capacity for tumor detection and delineation.
Results
Evaluation of Individual Modes in a Multimode Optical Imaging System
Fluorescence Intensity Imaging—Fluorescence intensity imaging has been performed
in order to identify the targeting capability of a nanoconstruct drug molecule [27, 28], which
is conjugated with Alexafluor 680, for brain tumors. For excitation, laser light at 647 nm
was utilized. An emission filter with a central wavelength of 705 nm and bandwidth of 20
nm was utilized for the detection of fluorescence from the drug molecules. After the drug
was injected into the tail vein of the mouse, the fluorescence of Alexafluor 680 was detected
in 24 h. Fig. 3a illustrates a typical pseudocolor image obtained through the fluorescence
intensity imaging mode, clearly showing that the drug molecules preferentially accumulate
into the brain tumors, as indicated by an arrow.
Spectral Imaging—We have extensive experience in pre-clinical and clinical spectral
imaging [33, 34]. The feasibility of spectral imaging in our new multimode system has been
investigated after 10 μM fluorescein, diluted with PBS (pH 7.4), was injected into breast
tumors implanted in the back of a nude mouse. 488nm laser light was utilized for the
excitation of fluorescein inside the mouse, and then a total of 12 images were recorded
within the spectral range of 500 to 720 nm with a step size of 20 nm. The images were
analyzed using software we developed. Spectral classification based on a least mean square
distances method was performed for separating fluorescein fluorescence from
autofluorescence. Fig. 3b shows the interpreted image obtained through spectral
classification: the fluorescence of fluorescein (red pseudocolor) is clearly discriminated
from autofluorescence (green pseudo-color).
Mosaic Fluorescence Lifetime Imaging Mosaic (field of view scanning)—FLIM
of the same mouse (used in the previous spectral imaging) was performed for the evaluation
of this imaging mode. Fig. 3c shows the fluorescence lifetime image displayed in
pseudocolor. While the fluorescence lifetimes from a mouse skin cluster around 3~3.8 ns,
the fluorescence lifetimes of fluorescein injected into tumor regions show values of 3.8~4.5
ns. In the image, the tumor regions with fluorescein are clearly distinguished from other
regions by the lifetime differences exhibited. Also, the lifetime values of fluorescein are in
good agreement with the those in literature [13].
Intravital Confocal Imaging—The feasibility of intravital confocal imaging of a rat
spine has been evaluated. After euthanizing the rat, its spine was exposed. Then,
autofluorescence images of the rat spine were recorded for 8 min by using an MKT S-probe
(0 μm working distance). The typical frame rate is 12 fps. Fig. 3d shows the results obtained
by using it. The image in Fig. 3d clearly shows skeletal muscle fibers and vessels around
spine regions, with high resolution.
Multiphoton (Scanning/WTEF) Imaging—Fig. 3e shows the results obtained by WTEF
imaging of a mouse intestine stained with Alexa 568 Phalloidin and scanning two-photon
excited fluorescence imaging of a mouse liver stained with fluorescein nonspecifically. In
the WTEF image, the filamentous actins are clearly shown like one-photon excited
fluorescence image we do not show here. The image size is approximately 80×65 μm.
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Moreover, the WTEF image (Fig. 3e, upper) corrected by the constructed mask shows
uniform baseline compared to that of the uncorrected image [32, 35]. Also, liver cell-like
structures stained with fluorescein are clearly shown in the scanning two-photon excited
fluorescence image (Fig. 3e, down).
Bioluminescence Imaging—Using bioluminescence mode in this system, we imaged
the presence of ATP and enzymatic activity in nude mice. After luciferin was injected into
their abdominal cavity, we took a photographic image and then recorded the
bioluminescence signal for 2 min. Fig. 3f shows the overlay of the photographic and
bioluminescence image. The result demonstrates the capability to record bioluminescence
signals with good signal-to-noise and versatility, opening up the possibility for further
studies using this modality.
Contrast Comparisons
In order to quantitatively evaluate the quality of the fluorescence images recorded, we
compared the contrast of tumor areas on the images of a mouse obtained with a commercial
system and our system. Here, we injected tumor targeting drug molecules into intra-vein of
the mouse, and then the images were acquired after 24 h. We compared the contrasts as
calculated with average intensities around tumor and non-tumor regions. The contrast values
calculated based on Michelson contrast [It(tumor) − Ib(background)/(Ib+Ib)] for the (best)
commercial system and our system are 0.33 and 0.66, respectively [28]. Our system’s
roughly two-fold improvement is not our highest ratio obtained, only a representative one.
Multi-mode Optical Imaging in Chemo- and Nanoconstruct Therapy Research for
Quantitative, Dynamic, and Functional Monitoring
Fluorescence Imaging of the Tumor Targeting Capability and Accumulation
Kinetics of Nanoconstructs—We monitored a nanoconstruct distribution in a nude
mouse with breast tumors after injection of the nanoconstructs conjugated with Alexafluor
680 into a tail vein in order to examine the tumor targeting capability and the accumulation
kinetics of the nanoconstructs. In the study [28], we could clearly distinguish the preferential
nanoconstruct accumulation in the tumor region in 3 h after its injection as well as observe
that the nanoconstructs were still retained in the tumor region after 24 h and perfusion. This
indicates that fluorescence intensity imaging enables dynamic monitoring of the
distributions of nanoconstructs in the tumors, thus allowing determination of their targeting
capability and accumulation kinetics.
Spectral Imaging for Quantitative Examination of Clearance of the
Nanoconstructs In Vivo and the Extent and Topology of HerGa Distribution
into Specific Organs and the Tumor—In chemotherapy assessment, drug clearance is
critical in the determination of dosage. We utilized here spectral imaging for monitoring
nanoconstruct temporal clearance from the whole mouse. For classification, the spectral
signatures of autofluorescence and Alexafluor 680 fluorescence were acquired before and
after nanoconstruct injection respectively. Fig. 4a shows the spectral signatures. Then, the
images before injection and at 10 min, 3h, and 24 h after injection were analyzed with the
spectral signatures. Fig. 4b shows the spectral classification images at those time points.
Before injection (0 h), autofluorescence was seen over the whole mouse. However, in 10
min after injection of nanoconstructs, the nanoconstructs (red pseudocolor) were distributed
over the overall mouse. The nano-constructs still remained over the whole area of the mouse
at 24 h. This result shows that spectral imaging and analysis provides better sensitivity and
specificity in the determination of the clearance of nanoconstructs, allowing detection of
minute drug amounts and of their changes.
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Investigation of the Extent and Topology of HerGa Distribution into Specific
Organs and the Tumor Using Multimode Optical Imaging Ex Vivo—We reported
that HerGa is very effective for tumor detection and delineation in HER2+ breast cancer
animal models. However, for the successful translation of HerGa chemotherapy into the
clinic, we need to do a better assessment, in vivo. Thus, we here evaluated the extent and
topology of HerGa distribution into specific organs and the tumor itself using multimode
optical imaging in order to examine the tumor targeting capability and tumor retention of
HerGa as well as drug effects on the other organs. Fig. 5a shows the fluorescence intensity
image at 620 nm. In the figure, HerGa is preferentially accumulated in tumors compared to
other organs, and the fluorescence signal from tumors is significantly higher than that from
liver. This figure clearly indicates that HerGa specifically and preferentially targets the
tumor and is better retained there. Fig. 5b shows the spectral classification image analyzed
with the predefined spectral signatures. In the image, while tumor and liver are clearly
classified as HerGa fluorescence, most areas of other organs are classified as
autofluorescence. The spectral imaging here offers better quantitative discrimination
between HerGa and autofluorescence than fluorescence intensity imaging. Fig. 5c shows
fluorescence lifetime images of the tumors and the liver. Here, other organs except for the
tumors and the liver are not considered for analysis since the signal from them is too low.
Fluorescence lifetime values of HerGa accumulated in tumors are significantly higher than
those in liver. In addition, the histograms of fluorescence lifetime in tumors and liver were
constructed for detailed examination (Fig. 5c), underscoring the higher HerGa lifetimes in
tumors vs. liver. This result may suggest the environmental information around tumor region
as well as the potential of HerGa in tumor detection and delineation. Finally, we performed
two-photon excited fluorescence imaging of tumors in order to examine them in detail with
high resolution. Fig. 5d shows the two-photon excited fluorescence image of tumor, clearly
showing the bright cellular structures due to HerGa accumulations. Taken together, these
results indicate that multimode optical imaging can provide complementary and highly
resolved information on tumor retention/accumulation of HerGa (intensity), quantitative
concentration (spectral), and tumor environment (lifetime), simultaneously, thus improving
the assessment of this chemotherapy molecule’s action.
Feasibility of Multimodal Optical Imaging of HerGa for Tumor Detection and
Delineation In Vivo—As shown previously, the multimodal optical imaging ex vivo
provides synergetic information in the assessment of HerGa, suggesting its potential for
tumor detection and delineation in vivo. Thus, we performed multimodal optical imaging
(fluorescence intensity, spectral, lifetime, and two-photon excited fluorescence imaging) of
HerGa for tumor detection and delineation, after the injection of HerGa into tumors and non-
tumor regions. Fig. 6 shows the images obtained by using multimodal optical imaging. The
fluorescence intensity and the spectral classification image (Fig. 6a, b) show the HerGa-
injected regions. In the fluorescence intensity image, we can observe HerGa relative
concentration in the injected regions (Fig. 6b). On the other hand, in the spectral
classification image, we can clearly distinguish HerGa localization more quantitatively and
specifically (Fig. 6a). Here, the injected regions are classified as red and blue pseudocolor,
indicating highly concentrated accumulation of HerGa compared to autofluorescence (A•F)
[36]. In addition, we performed two-photon excited fluorescence imaging of a tumor region
(region 1) of the mouse shown in Fig. 6d. The two-photon excited fluorescence images
provide highly resolved information around the tumor regions where HerGa accumulates.
Most importantly, the fluorescence lifetimes (1.9–2.2 ns) of HerGa in tumors (region 1 and
2) are higher than those (1.2–1.5 ns) in muscles (region 3). Thus, we can discriminate
between the tumors and normal regions by the fluorescence lifetime difference. This shows
the potential of HerGa for the tumor detection and delineation, with additional potential for
assessing micro-environmental status in the tumors such as pH and oxygenation.
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Discussion and Conclusions
The work described here validates the design and functionality of our multimode imaging
system and shows that it can be optimized for various applications, benefiting from the
performance of each individual imaging mode, as well as the synergetic possibilities enabled
by the multimode approach. In Fig. 3a, the drug molecules accumulated in the brain tumor
were clearly distinguished, allowing establishment and monitoring of their brain tumor
targeting capacity in vivo. In addition, this imaging mode in our system provided
significantly better contrast than the leading commercial imaging systems, mostly due to
versatile wavelength selection. In our multimode imaging system, the spectral capability
enhances quantitation ability in small animal imaging, as shown in Fig. 3b. In the image, the
regions where fluorescein is accumulated are clearly delineated by the spectral
classification. This imaging capability can correctly measure corrected fluorescence
intensity under severe background noise conditions (autofluorescence or other
fluorophores), as we first proposed many years ago. In addition, we have incorporated FLIM
capability into our system in order to obtain additional information including the
environment surrounding our molecules of interest. Using this mode, we could also
discriminate fluorescein from autofluorescence in a nude mouse (Fig. 3c). Furthermore, this
imaging mode can be used for monitoring tissue functional status in the vicinity of
fluorophores [13, 17, 37]. Intravital confocal imaging has also demonstrated its usefulness
for detecting structural and functional (including pathological) information in multimode
optical imaging (Fig. 3d). Microstructures such as skeletal muscle fibers or vessels were
observed using this imaging mode without a biopsy. Thus, the convergence of modes allows
monitoring of intact tissues inside small animals with high magnification and resolution.
Scanning/WTEF imaging can further enhance this, by providing better contrast and more
penetration depth than one-photon excited fluorescence imaging in our system [20, 35].
When compared to scanned two-photon excitation, the speed of WTEF imaging has the
advantage of reducing any artifacts due to the movement of animals during in vivo image
acquisition. Thus, it may be highly useful for in vivo imaging even though its resolution is
less than that of scanning two-photon excited fluorescence imaging. In addition,
bioluminescence imaging, combined with fluorescence measurements, could allow
improved bioluminescence resonance transfer (BRET) studies.
We have shown that the multimode optical imaging system can be specifically useful for the
assessment of chemotherapy molecules of promise since it allows simultaneous use of
multiple imaging modes (fluorescence intensity, spectral, fluorescence lifetime, and two-
photon excitation imaging), yielding complementary information. In this paper, the tumor
targeting capability, retention, clearance, and functional characteristics of chemotherapy
molecules were investigated using in the multimode advantages of our system. In a previous
study [28], we could monitor the dynamic accumulation of nanoconstructs over the whole
mouse in real time. The nanoconstructs were preferentially accumulated in the tumor region,
and we could identify their targeting capability using the fluorescence intensity imaging
mode. Here, in addition, nanoconstruct clearance from the mouse was examined using
spectral imaging at different time points after nanoconstruct IV injection, yielding more
accurate information than fluorescence intensity imaging at a single wavelength (Fig. 4),
since spectral imaging is sensitive to molecular signatures and more quantitative. We have
already reported the use of spectral imaging in the evaluation of accumulation of
nanoconstructs into different organs excised from a mouse that received the nanoconstructs
through IV injection [33]. In that previous report, spectral image analysis and spectral
unmixing method confirmed the fact that the nanoconstructs accumulate specifically in the
tumor region and excreting organs like spleen, liver, and kidney, but not in the brain, lung,
and heart [33]. In this paper, we utilized spectral imaging in order to examine the extent and
topology of HerGa distribution into specific organs and the tumor itself, both ex vivo and in
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vivo. HerGa is an intensely fluorescent macrocyclic compound that spontaneously
assembles with carrier proteins to undergo cell entry. Previously, we observed that the
HerGa was preferentially accumulated in breast tumors compared to S2Ga as judged by
fluorescence intensity imaging [30]. We confirmed here the drug effects on specific organs
using spectral imaging, which provided better quantitative information than standard
fluorescence intensity imaging as shown in Fig. 5. While HerGa was clearly shown in whole
tumors and in some parts of the liver, HerGa was very sparse in other organs (kidney, lung,
heart, spleen, and muscle). Furthermore, FLIM has been performed in order to acquire
surrounding tissue information (acidity and/or oxygenation) around tumor regions since
fluorescence lifetimes of HerGa depends on pH. The fluorescence lifetimes of HerGa
accumulated in the tumors are higher than in the liver (Fig. 5c), and also appear higher than
in non-tumor regions in vivo (data not shown). The histogram of fluorescence lifetimes in
tumor regions has a greater population at 2.0 ns than in non-tumor regions. Differences are
reproducible, and probably underestimated, as the lifetime values may be affected by skin
since the fluorescence lifetime values we obtained are the average values from skin, tumor,
and muscle. If the skin is removed, the difference of the fluorescence lifetime values of
HerGa in tumor and non-tumor regions may become larger. In order to confirm this, we
have conducted FLIM measurements after HerGa injection into tumors and normal tissues.
In Fig. 6c, the fluorescence lifetime difference of HerGa in the tumors and normal tissues is
clearly distinguished. This result verifies that HerGa fluorescence lifetimes in tumors differ
from those in normal tissues since tumor regions may be more acidic and hypoxic than
normal tissues. Finally, scanning two-photon excited fluorescence imaging of tumor regions
provides high magnification and resolution topological detail of the regions of interest: in
Fig. 5d, we can clearly see microstructures in the tumors. Eventually, when translated to the
clinic, this may help a physician’s decision-making in cancer surgical intervention and
detection without the need for rapid histopathological analysis of tissue biopsy during
surgery. Also, the fluorescence lifetime difference of HerGa in tumors and liver opens the
possibility of HerGa being used for cancer (margin) detection and delineation.
Furthermore, in order to confirm the feasibility of tumor detection using multimodal optical
imaging of HerGa in vivo, we used our system after HerGa injection into tumors and a non-
tumor region. In Fig. 6, the tumor and non-tumor regions are clearly distinguished in the
fluorescence lifetime image, but not as well in the other images. This suggests that HerGa
fluorescence lifetimes in tumor certainly differ from those in normal tissues since tumor
regions may be more acidic and hypoxic than normal tissues. Additionally, fluorescence
intensity, spectral, and scanning two-photon excited fluorescence imaging here provide
complementary information to the FLIM such as the relative injection of HerGa, HerGa
localization, and HerGa distribution with high resolution and magnification at different
depths.
In conclusion, we have developed and tested an advanced optical imaging system that
allows functional multiscale imaging (under-the-surface whole-body or endoscopic imaging
with microscopic resolution) of small animals in vivo. The multimode optical imaging
system, whose concept was derived from our previous work in microscopy [38], can be
utilized and optimized for various applications. Furthermore, the combination of
fluorescence intensity, spectral, lifetime, and two-photon excited fluorescence imaging can
provide complementary, dynamic, quantitative, functional, and highly resolved information
for an assessment of nano-constructs and chemotherapy molecules. These capabilities may
also enhance contrast in detecting diseased tissues or in evaluation of drug effects in
chemotherapy. In this system, other imaging modes such as 3D volumetric fluorescence
imaging, elastic scattering imaging, spinning disk confocal imaging, and Raman or time-
gated photon propagation also can be included for more versatility and applications.
Particularly, we already have constructed optical components and developed a program to
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enable acquisition of fluorescence images at different angles for the 3D volumetric
fluorescence imaging and obtained preliminary results (data not shown). However, highly
sophisticated simulations will be needed for 3D fluorescence volumetric imaging [5, 39].
This work will allow monitoring of volumetric tumor growths in vivo. Also, our scanning/
wide-field two-photon excited fluorescence imaging unit needs to be better incorporated into
the system in order to minimize animal disturbance during the experiment. Finally, the
multimode optical imaging of HerGa suggests the possibility as a novel method for cancer
detection and treatments. For clinical studies, optimization for sensitivity and specificity,
and better, more time-critical decision-making in cancer management is needed. For this, a
multimode optical imaging system for a human (clinical) use should be designed. For
surgical detection and intervention, our multimode approach can be combined with an
endoscope or surgical microscope [40–42].
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Fig. 1.
Multimode optical imaging system. a System schematic. This system is capable of several
imaging modes, including fluorescence intensity, spectral, life time, intravital confocal, and
bioluminescence imaging. Also, for 3D fluorescence imaging, optical components and a
control program are installed. Furthermore, scanning/WTEF imaging mode will be
incorporated with the system for deep tissue imaging at high resolution. b Photographic
image of the multimode optical imaging system. MFW motorized filter wheel, RL relay
lens, TCL telecentric lens, ER mode exchange rail, GM galvo mirror, TL tube lens, F1 band-
pass filter, F2short-pass filter, DM dichroic mirror, L doublet lens, HP heating pad, D
diffuser, RS rotational stage, FR faraday rotator, R retarder, RF rotational filters, BS beam
sampler, ET external trigger for FLIM.
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Fig. 2.
Experimental setup of each mode. a Fluorescence imaging mode. Selected light sources
divided by a 50:50 dichroic mirror in a light-tight enclosure are delivered into a specimen
through two diffusers. Then, fluorescence collected by a telecentric lens from a specimen is
recorded in CCD through a selected filter. b Spectral imaging mode. An excitation method
procedure is identical with the method in fluorescence intensity imaging. AOTF is employed
between a filter and CCD for band-sequential spectral selection. c mosaic FLIM using fs
pulsed laser light. fs pulsed laser light was used for the excitation of the molecules of
interest. A specimen was scanned by x–y translation motorized stage for LFOV controlled
by the developed program, which is connected with the actuation motor control program
through a TCP/IP internet connection. d Intravital confocal imaging mode. S-probe with a
diameter, 0.65 mm is utilized for intravital confocal imaging. The probe has 0 μm working
distance, 5 μm lateral resolution, and 15 μm axial resolution. The image obtained using the
probe has 599×500 μm field of view and 450×384 pixels. e Scanning/WTEF imaging
modes. L1 is a doublet lens that enables wider excitation and is removed in scanning two-
photon imaging mode. F1 and F2 are shortpass filter (<700 nm) and interference filter,
respectively. L2 is a tube lens. f Bioluminescence imaging modes. Bioluminescence signal is
collected by a telecentric lens, and then recorded in the cooled CCD. After bioluminescence
imaging is completed, a photographic image is acquired with LED illumination for
overlaying with the bioluminescence image.
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Fig. 3.
Images obtained by using each mode of multimode optical imaging system. a Fluorescence
intensity image of the drug molecules preferentially accumulating into implanted brain
tumors in the mouse. The arrow indicates a brain tumor. b Spectral classification image of a
nude mouse with injection of fluorescein into implanted tumors and an engineered mouse
pup with GFP expression. While red pseudocolor represents fluorescence of fluorescein (the
left image) and GFP (the right image), green pseudocolor represents autofluorescence. c
Fluorescence lifetime image obtained by mFLIM. The mouse was scanned by the system
step-by-step for LFOV. Two sets of images were merged into a single image. For each
fluorescence lifetime image, a total of 39 images have been acquired within 0 to 7,800 ps
with a time step, 200 ps. d Intravital confocal image of a rat spine. The image (skeletal
muscles) was extracted from the video file recorder for 8 min. e WTEF images (scale bar, 50
μm) of a mouse intestine and scanning two-photon excited fluorescence image (scale bar,
100 μm) of a mouse liver stained with fluorescein. A WTEF image (upper) is acquired with
795 nm excitation pulsed laser and an emission filter (620±60 nm), and then a flat-field
corrected image was generated by a constructed Gaussian mask. For the scanning two-
photon excitation of the liver, fs pulsed laser light at 780 nm was here used, and a shortpass
filter (<700 nm) and a bandpass filter (540±40 nm) were utilized for the emission light
selection. A Nikon 40× (NA: 0.75) and a Nikon 20× objective (NA: 0.50) were used for
WTEF and scanning two-photon excited fluorescence imaging, respectively. f
Bioluminescence image from engineered mice (normalized by highest value).
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Fig. 4.
Clearance examination of the drug nanoconstruct using spectral imaging. a Spectral
signatures of autofluorescence and fluorescence of Alexafluor 680. The spectral signature of
autofluorescence and Alexafluor 680 fluorescence is obtained from a spectral image cube
(700 to 790 nm) acquired before and after intravenous injection of the nanoconstruct
respectively. b Spectral classification images at different time points. A total of 13 images
were recorded within the spectral range of 705 to 789 nm with a step size 7 nm at different
time points (0 h, 10 min, 3 h, and 24 h). Then, those images were analyzed with the
previously acquired signatures using our developed program. Here, while green pseudocolor
represents autofluorescence, red pseudocolor represents Alexafluor 680.
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Fig. 5.
Specific organs and tumor images obtained using multi-mode optical imaging. a
Fluorescence intensity image of organs and tumors at 620 nm. b Spectral classified image. A
total of ten images were recorded within the spectral range of 500 to 680 nm with a step size
of 20 nm. Then, the images were analyzed using software we developed. While the red color
represents HerGa fluorescence, the green color represents autofluorescence. Spectral
signatures of autofluorescence (green) and HerGa (red) were extracted from a pre-
constructed signature library. c Fluorescence lifetime images of tumors and liver (the upper
image) and the fluorescence lifetime histograms (the lower image). d Two-photon excited
fluorescence image of tumors. The image of tumor was acquired using fs pulsed laser at 848
nm, an emission filter with 620±60 nm, Nikon 60× objective.
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Fig. 6.
Multimodal optical imaging for cancer detection and delineation of HerGa. a Spectrally
classified image. This spectral classified image was obtained through using the signatures
(left side) constituted of various ratios of autofluorescence and HerGa fluorescence. b
Fluorescence intensity image. c Fluorescence lifetime image. HerGa injection area: (1)
tumor, (2) tumor, and (3) non-tumor. d Two-photon excited fluorescence images of tumor
regions. These two-photon excited fluorescence images of tumor were acquired at the
different focal planes (20, 40, 60, 80, 100, and 120 μm; ex, 848 nm; em, 620±60 nm, and
Nikon 60× objective). The scale bar represents 50 μm.
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